Theravance, Inc. (THRX) Misses Q2 Views; Loss Wider than Expected
Tweet
Share
E-mailGet Alerts THRX Hot Sheet
Price: $4.06 --0%
Financial Fact:
Research and development: 286K
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Research and development: 286K
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Theravance, Inc. (NASDAQ: THRX) reported Q2 loss of ($0.31), $0.03 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $6.4 million versus the consensus estimate of $8.86 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Beyond Air, Inc. (XAIR) Tops Q1 reported Q1 Revenue ; Offers Guidance
- Intuitive Machines, Inc. (LUNR) Misses Q2 EPS by 20c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
